Oxybutynin Chloride Topical Gel Improves Quality of Life for Women With Overactive Bladder: Presented at ACOG
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Oxybutynin Chloride Topical Gel Improves Quality of Life for Women With Overactive Bladder: Presented at ACOG

By Bruce Sylvester

CHICAGO -- May 12, 2009 -- Treatment with oxybutynin chloride topical gel (OTG) results in significant improvement in health-related quality of life (HRQOL) in women with overactive bladder, researchers stated here on May 5 at the 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG).

Vincente Lucente, MD, The Institute for Female Pelvic Medicine and Reconstructive Surgery, Allentown, Pennsylvania, and colleagues studied the effects of OTG on women with overactive bladder in a 12-week, randomised, double-blind, parallel-group, multicentre trial.

The study included 789 patients aged 18 years and older (mean 59 +- 12 years) and diagnosed with urge-predominant urinary incontinence. Of the patients, 704 were women.

Half of the women received OTG 1 g/day (~4 mg/day), and the other half received a placebo.

To measure HRQOL, patients were asked to fill out the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire (KHQ) at baseline and subsequent clinic visits.

The 4 IIQ subscale scores (range 0-100) were combined to determine an IIQ total score (range 0-400). The 10 KHQ domains had a score range of 0 to 100. Standard statistical tools were used to analyse the data.

At 12 weeks, the IIQ total score of women treated with OTG (-73.3) was significantly decreased compared with women receiving placebo (-47.8; P = .0001); scores on all 4 IIQ subscales were also significantly lower for the OTG-treated group (P < .01).

KHQ scores decreased significantly more in 6 of 10 domains for OTG than placebo (P = .02).

The researchers concluded that OTG significantly beneficial in enhancing HRQOL of women with overactive bladder.

[Presentation title: Quality of Life Assessment in Women With OAB After Treatment With Oxybutynin Chloride Topical Gel. Abstract 110]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities